Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 1;32(19):2074-7.
doi: 10.1200/JCO.2014.55.7652. Epub 2014 May 27.

Two dimensions in targeting HER2

Mark M Moasser  1
Affiliations

Two dimensions in targeting HER2

Mark M Moasser. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Structure of the human epidermal growth factor receptor 2 (HER2) and HER3 receptors and their mode of activation through dimerization and activation of PI3K/Akt signaling and binding sites of trastuzumab, pertuzumab, and lapatinib, showing both an inactive and ligand-activated HER3. Binding of ligand reconfigures the extracellular domain of HER3, exposing the dimerization interface. The extracellular domain of HER2 is always in the active configuration and does not require ligand. The phosphorylated signaling tail of HER3 binds and activates PI3K, leading to phosphorylation of membrane lipids, which is reversed by the phosphatase PTEN. These membrane phospholipids recruit and activate Akt, which regulates many downstream events. In HER2-driven cancer cells, it also regulates HER3 in a feedback loop shown by the arrow.
See this image and copyright information in PMC

References

    1. Moasser MM. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469–6487. - PMC - PubMed
    1. Ursini-Siegel J, Schade B, Cardiff RD, et al. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer. 2007;7:389–397. - PubMed
    1. Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003;100:8933–8938. - PMC - PubMed
    1. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res. 2008;68:5878–5887. - PubMed
    1. Vaught DB, Stanford JC, Young C, et al. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res. 2012;72:2672–2682. - PMC - PubMed

MeSH terms